Manufacturer record
Medreich Limited: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Medreich Limited (Karnataka) were declared Not of Standard Quality between February 2023 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
2 records linked to Medreich Limited in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Amoxycillin & Potassium Clavulanate Tablets IP | 826D074Mfg 2026-03 · Exp 2027-08 | Identification - Doesn't conforms to I.P.Identification | Lucknow LabState lab | Jul 2026 |
| AUGMENTIN 625 DUO (Amoxycillin and Potassium Clavulanate Tablets IP) | MK 203Mfg 2022-04 · Exp 2023-09 | Identification and AssayAssay | CDL KolkataCDSCO lab | Feb 2023 |
Batches reported as suspected spurious under this label
CDSCO's spurious-drug alerts list batches that purport to be made by a company but are suspected counterfeits. The labelled manufacturer's reply is shown where CDSCO published it.
| Product | Batch | Reported by | Firm's reply | Alert |
|---|---|---|---|---|
| Amoxycillin and Potassium Clavulanate Tablets IP | 825D167 | CDL, Kolkata | The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. | May 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.